<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75464">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01795144</url>
  </required_header>
  <id_info>
    <org_study_id>12-1517</org_study_id>
    <nct_id>NCT01795144</nct_id>
  </id_info>
  <brief_title>Incretin Regulation of Insulin Secretion in Monogenic Diabetes</brief_title>
  <official_title>Incretin Regulation of Insulin Secretion in Monogenic Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the mechanisms of metabolic control in monogenic
      diabetes patients treated with sulfonylurea medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monogenic diabetes patients and healthy matched controls will be admitted to the University
      of Chicago Clinical Resource Center for a total of 4 nights.  The following will take place
      on separate days:

        1. Oral Glucose Tolerance Test (OGTT): consume sugary drink and blood samples will be
           collected at multiple time points

        2. Isoglycemic glucose infusion (IGI) test: glucose will be infused via a vein in the arm
           and and blood samples will be collected at multiple time points

        3. OGTT during GLP-1 infusion

        4. IGI during Exendin-9 infusion
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Incretin Effect</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Directly calculated from the difference between oral and IV stimulated insulin secretion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Monogenic Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects.  Healthy controls will participate in the following:
OGTT
IGI
IGI with GLP-1 infusion
OGTT with Exendin 9-39 infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monogenic diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls.  Monogenic diabetes subjects will participate in the following:
OGTT
IGI
IGI with GLP-1 infusion
OGTT with Exendin 9-39 infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Monogenic diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin 9-39</intervention_name>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Monogenic diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Monogenic Diabetes Subjects:

        Inclusion Criteria:

          -  Diagnosis of monogenic diabetes

          -  Previously participated in US Neonatal Diabetes Registry (IRB 15617B) or Genetics of
             diabetes mellitus (IRB 6858)

          -  Age: 18 years +

        Exclusion Criteria:

          -  Pregnancy

          -  Acute medical illness or chronic conditions including: cardiac failure, renal
             insufficiency (estimated glomerular filtration rate &lt;50 ml/min), hepatic
             insufficiency (known cirrhosis or hepatitis), chronic obstructive pulmonary disease,
             gastrointestinal disorders causing malabsorption, anemia (Hct &lt; 36%), or uncontrolled
             hypertension

        Healthy Controls:

        Inclusion Criteria:

          -  Good general health

          -  Stable weight for 6 months

          -  Age: 18 years +

        Exclusion Criteria:

          -  Pregnancy

          -  Acute medical illness or chronic conditions including: cardiac failure, renal
             insufficiency (estimated glomerular filtration rate &lt;50 ml/min), hepatic
             insufficiency (known cirrhosis or hepatitis), chronic obstructive pulmonary disease,
             gastrointestinal disorders causing malabsorption, anemia (Hct &lt; 36%), or uncontrolled
             hypertension
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siri Atma W Greeley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Devine, RN</last_name>
    <phone>773-795-4417</phone>
    <email>ndevine@peds.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siri A Greeley, MD, PHD</last_name>
      <phone>773-702-1000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>February 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
